You are here

ASH2021

4 Biotechs That Were Winners at ASH

Motley Fool

Mon, 01/3/22 - 10:38 am

Bristol Myers Squibb

Agios Pharmaceuticals

Forma Therapeutics

sickle cell disease

Multiple Myeloma

ASH 2021 movers – IGM steals the show, for all the wrong reasons

EP Vantage

Thu, 12/16/21 - 10:46 am

IGM Biosciences

ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma

Endpoints

Tue, 12/14/21 - 11:12 am

antibody-drug conjugate

ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients

Endpoints

Mon, 12/13/21 - 11:47 pm

ASH 2021 – Bluebird looks to revive Lentiglobin

EP Vantage

Mon, 12/13/21 - 10:34 am

sickle cell disease

ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma

Fierce Pharma

Sun, 12/12/21 - 11:33 pm

Multiple Myeloma

ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio

Endpoints

Sun, 12/12/21 - 11:31 pm

bispecific antibodies

ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field

Endpoints

Sun, 12/12/21 - 11:26 pm

Precision Biosciences

relapsed or refractory non-Hodgkins lymphoma

ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe

Fierce Pharma

Sat, 12/11/21 - 09:15 pm

What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

OBR Oncology

Wed, 11/24/21 - 10:23 am

Ash 2021 preview – small increases and big falls

EP Vantage

Mon, 11/8/21 - 10:50 am

Global Blood Therapeutics

IGM Biosciences

Global Blood takes on gene therapy

EP Vantage

Thu, 10/28/21 - 10:36 am

Global Blood Therapeutics

sickle cell disease